NIPT TEST FOR FETAL TRISOMY13,18,21

NIPT Test for Fetal Trisomy 13, 18, 21 is an advanced non-invasive prenatal screening test designed to assess the risk of common fetal chromosomal abnormalities using a simple maternal blood sample. The test analyzes cell-free fetal DNA (cffDNA) circulating in the mother's bloodstream and provides highly accurate screening for Trisomy 21 (Down Syndrome), Trisomy 18 (Edwards Syndrome), and Trisomy 13 (Patau Syndrome).

Non-Invasive Prenatal Testing (NIPT) offers expectant parents a safe and reliable method of prenatal genetic screening without the risks associated with invasive procedures such as amniocentesis or chorionic villus sampling (CVS). The test can be performed as early as 10 weeks of pregnancy and provides valuable information regarding fetal chromosomal health.

Benefits of the Test

• Non-invasive and safe for both mother and fetus.
• Highly accurate screening for Trisomy 13, 18, and 21.
• Requires only a maternal blood sample.
• Can be performed from 10 weeks of pregnancy onward.
• Reduces the need for unnecessary invasive procedures.
• Provides early prenatal genetic information.
• Supports informed pregnancy management decisions.
• Offers high sensitivity and specificity compared to traditional screening methods.

Why Doctors Recommend This Test

Doctors recommend NIPT for pregnant women seeking early prenatal chromosomal screening, women of advanced maternal age, pregnancies with abnormal ultrasound findings, positive conventional screening results, family history of chromosomal abnormalities, or those desiring additional reassurance regarding fetal chromosomal health.

The test helps identify pregnancies at increased risk for common chromosomal abnormalities and guides further clinical evaluation when necessary.

Preparation Before Test

• No fasting is required.
• A maternal blood sample is collected for analysis.
• The test is generally performed after completion of 10 weeks of gestation.
• Provide relevant pregnancy and medical history.
• Inform your doctor about twin pregnancy, IVF conception, or previous transplant history if applicable.
• Genetic counseling may be recommended before or after testing.

Normal Reporting Time

Most NIPT Test for Fetal Trisomy 13, 18, 21 reports at Focus Diagnostics are initiated within 2–3 hours of sample receipt for processing and quality assessment. Final genomic analysis, interpretation, and reporting are generally completed within 5–10 working days depending on laboratory workflow and quality control requirements.

Who Should Take This Test?

This test may be recommended for:

• Pregnant women from 10 weeks gestation onward.
• Women aged 35 years or older during pregnancy.
• Pregnancies with abnormal first-trimester screening results.
• Pregnancies with suspicious ultrasound findings.
• Couples with a family history of chromosomal abnormalities.
• Women seeking advanced prenatal screening.
• IVF pregnancies requiring prenatal genetic assessment.
• Individuals wishing to reduce the need for invasive prenatal testing.

Detailed Information

Chromosomes are structures within cells that contain genetic material. Humans normally have 46 chromosomes arranged in 23 pairs. Trisomy occurs when an extra copy of a chromosome is present, resulting in three copies instead of the normal two.

Trisomy 21, also known as Down Syndrome, is the most common chromosomal condition screened by NIPT and is associated with characteristic physical features, developmental delay, and varying degrees of intellectual disability. Trisomy 18 (Edwards Syndrome) and Trisomy 13 (Patau Syndrome) are less common but often associated with severe congenital abnormalities and significant medical complications.

During pregnancy, fragments of fetal DNA circulate naturally within maternal blood. NIPT analyzes these cell-free fetal DNA fragments using advanced genomic technologies to estimate the risk of chromosomal abnormalities. Because only a maternal blood sample is required, the procedure poses no direct risk to the fetus.

NIPT is considered a screening test rather than a diagnostic test. A high-risk result does not confirm the presence of a chromosomal abnormality, and a low-risk result does not completely eliminate the possibility. Diagnostic confirmation through procedures such as amniocentesis or chorionic villus sampling may be recommended when abnormal screening results are obtained.

The test offers significantly higher sensitivity and specificity than traditional maternal serum screening methods and has become an important component of modern prenatal care.

Results should always be interpreted in conjunction with gestational age, ultrasound findings, clinical history, and genetic counseling. Healthcare providers may recommend additional testing depending on individual circumstances.

At Focus Diagnostics, NIPT testing is performed using advanced genomic technologies, validated molecular methodologies, and stringent quality assurance standards to provide accurate, reliable, and clinically meaningful prenatal screening results.